Key Highlights
- Lantern Pharma (NASDAQ:LTRN) reported third-quarter Net Income of USD 0.7 million, or USD 0.05 a share basic, against a net loss of USD 4.2 million a year earlier, despite a USD 5.4 million operating loss.
- A USD 6.0 million gain from the change in Fair Value of its Warrant Liability produced the profit, while diluted loss per share was USD 0.37 for the quarter.
- General and administrative expense rose to USD 3.8 million from USD 1.9 million, while Research and Development fell to USD 1.6 million from USD 2.4 million in the third quarter.
- Cash and equivalents were USD 7.6 million at September 30, 2026, and management said resources will not fund operations for 12 months, creating substantial doubt about continuing as a going concern.
A Warrant Fair Value Gain Lifts a Loss-Making Quarter Into Profit
Lantern Pharma (NASDAQ:LTRN) reported net income of USD 696 thousand for the quarter ended September 30, 2026, compared with a net loss of USD 4.2 million a year earlier. The loss from operations was USD 5.4 million, wider than USD 4.3 million, and the gap was closed by a USD 6.0 million gain on the change in fair value of the warrant liability. The company develops cancer drug candidates and uses its RADR platform to identify drug candidates and patient populations. Interest income was USD 27 thousand, down from USD 101 thousand. The Quarterly Report was filed on November 17, 2026.
Spending Shifts From Research to Administration
General and administrative expense for the third quarter was USD 3.8 million against USD 1.9 million, while research and development expense fell to USD 1.6 million from USD 2.4 million. For nine months, the net loss narrowed to USD 9.7 million, or USD 0.78 a share, from USD 13.0 million, or USD 1.21 a share. Total operating expenses for the nine months were USD 12.3 million against USD 13.8 million. The nine-month result also includes a USD 3.9 million warrant fair value gain, partly offset by USD 726 thousand of loss on issuance of warrants and USD 755 thousand of warrant issuance costs.
Thin Liquidity, a USD 4.0 Million Offering and Going Concern Doubt
Cash and cash equivalents were USD 7.6 million, up from USD 4.4 million at December 31, 2025, with Working Capital of about USD 2.8 million and stockholders' Equity of USD 1.4 million. In September 2026 the company completed a registered direct offering of shares and pre-funded warrants for gross proceeds of about USD 4.0 million before roughly USD 393 thousand of expenses. It also has an at-the-market agreement with ThinkEquity. Management says cash will not fund operations for 12 months, which raises substantial doubt about continuing as a going concern. There were 15,886,576 shares outstanding as of November 9, 2026.
Where Things Stand
Lantern Pharma (NASDAQ:LTRN) turned a profit because a USD 6.0 million non-cash gain on its warrant liability outweighed a USD 5.4 million operating loss, so the result does not signal operating improvement. The diluted loss of USD 0.37 a share shows the underlying picture. Nine-month losses narrowed to USD 9.7 million, yet the accumulated Deficit stands at USD 102.8 million and cash would not last 12 months. Next markers are further sales under the ThinkEquity facility, additional capital raises and how warrant values move.


_11_18_2026_14_48_04_195267.jpg)



Please wait processing your request...